THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

If you are in any doubt as to any aspect of this circular or as to the action to be taken, you should consult a stockbroker or other registered dealer in securities, a bank manager, solicitor, professional accountant or other professional adviser.

If you have sold or transferred all your shares in MicroPort Scientific Corporation, you should at once hand this circular, together with the enclosed form of proxy, to the purchaser or transferee or to the bank, stockbroker or other agent through whom the sale or transfer was effected for transmission to the purchaser or transferee.

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this circular.

MicroPort®

MicroPort Scientific Corporation

微創醫療科學有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 00853)

PROPOSED RE-ELECTION OF RETIRING DIRECTORS, PROPOSED ELECTION OF AN INDEPENDENT NON-EXECUTIVE DIRECTOR, PROPOSED RE-APPOINTMENT OF AUDITOR, PROPOSED GRANTING OF GENERAL MANDATES TO BUY BACK SHARES AND TO ISSUE SHARES, AND NOTICE OF ANNUAL GENERAL MEETING

A notice convening the Annual General Meeting of MicroPort Scientific Corporation to be held at 1601 Zhangdong Road, Zhangjiang Hi-Tech Park, Shanghai 201203, the People's Republic of China on 30 June 2026 (Tuesday) at 10:00 a.m. is set out on pages 19 to 23 of this circular. A form of proxy for use at the Annual General Meeting is also enclosed. Such form of proxy is also published on the websites of Hong Kong Exchanges and Clearing Limited (www.hkexnews.hk) and the Company (www.microport.com).

Whether or not you are able to attend the Annual General Meeting, please complete and sign the enclosed form of proxy in accordance with the instructions printed thereon and return it to the Company's branch share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong as soon as possible but in any event not later than 10:00 a.m. on 28 June 2026 (Sunday) (Hong Kong time). Completion and return of the form of proxy will not preclude Shareholders from attending and voting in person at the Annual General Meeting if they so wish.

* *for identification purpose only*

8 June 2026

CONTENTS

Page

Definitions 1

Letter from the Board

1. Introduction 3
2. Proposed Re-election of Retiring Directors 4
3. Proposed Election of an Independent Non-executive Director 5
4. Proposed Re-appointment of Auditor 5
5. Proposed Granting of the Share Buy-back Mandate 6
6. Proposed Granting of the Issuance Mandate 6
7. Responsibility Statement 6
8. Annual General Meeting and Proxy Arrangement 7
9. Recommendation 8

Appendix I – Details of the Directors Proposed for Re-election and Election 9

Appendix II – Explanatory Statement on the Share Buy-back Mandate 16

Notice of Annual General Meeting 19

In this circular, unless the context otherwise requires, the following expressions shall have the following meanings:

"Annual General Meeting"	the annual general meeting of the Company to be convened and held at 1601 Zhangdong Road, Zhangjiang Hi-Tech Park, Shanghai 201203, the People's Republic of China on 30 June 2026 (Tuesday) at 10:00 a.m., to consider and, if appropriate, to approve the resolutions contained in the notice of the meeting which is set out on pages 19 to 23 of this circular, or any adjournment thereof
"Articles of Association"	the articles of association of the Company currently in force
"associates"	has the meaning ascribed thereto under the Listing Rules
"Board"	the board of Directors
"CCASS"	the Central Clearing and Settlement System established and operated by Hong Kong Securities Clearing Company Limited
"Company"	MicroPort Scientific Corporation, a company incorporated in the Cayman Islands with limited liability, the Shares of which are listed on the Main Board of the Stock Exchange
"core connected person(s)"	has the meaning ascribed thereto under the Listing Rules
"Director(s)"	the director(s) of the Company
"Group"	the Company and its subsidiaries
"HK$"	Hong Kong dollars, the lawful currency of Hong Kong
"Hong Kong"	the Hong Kong Special Administrative Region of the PRC
"Issuance Mandate"	a general mandate proposed to be granted to the Directors to allot, issue and deal with additional Shares and/or to resell treasury shares of the Company (if permitted under the Listing Rules) of not exceeding 20% of the total number of Shares of the Company in issue (excluding treasury shares) as at the date of passing of the proposed ordinary resolution contained in item 7 of the notice of the Annual General Meeting as set out on pages 19 to 23 of this circular
"Latest Practicable Date"	2 June 2026, being the latest practicable date prior to the printing of this circular for ascertaining certain information in this circular

"Listing Rules"	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited as amended, supplemented or otherwise modified from time to time
"Memorandum of Association"	the memorandum of association of the Company currently in force
"PRC"	the People's Republic of China, which for the purpose of this circular, shall exclude Hong Kong, the Macau Special Administrative Region of PRC and Taiwan
"SFO"	the Securities and Futures Ordinance, Chapter 571 of the Laws of Hong Kong
"Share(s)"	ordinary share(s) of nominal value of US$0.00001 each in the capital of the Company or if there has been a subsequent sub-division, consolidation, reclassification or reconstruction of the share capital of the Company, shares forming part of the ordinary equity share capital of the Company
"Shareholder(s)"	holder(s) of Share(s)
"Share Buy-back Mandate"	a general mandate proposed to be granted to the Directors to buy back Shares on the Stock Exchange of not exceeding 10% of the total number of Shares of the Company in issue (excluding treasury shares) as at the date of passing of the proposed ordinary resolution contained in item 6 of the notice of the Annual General Meeting as set out on pages 19 to 23 of this circular
"Stock Exchange"	The Stock Exchange of Hong Kong Limited
"Takeovers Code"	the Codes on Takeovers and Mergers approved by the Securities and Futures Commission as amended from time to time
"treasury shares"	has the meaning ascribed thereto under the Listing Rules
"%"	per cent

MicroPort®

MicroPort Scientific Corporation

微創醫療科學有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 00853)

Executive Director:
Dr. Zhaohua Chang *(Chairman)*

Non-executive Directors:
Dr. Feng Gu
Dr. Qingbing Men
Ms. Weiqin Sun

Independent Non-executive Directors:
Mr. Jonathan H. Chou
Dr. Guoen Liu
Mr. Chunyang Shao

Registered Office:
P.O. Box 309, Ugland House
Grand Cayman, KY1-1104
Cayman Islands

Head Office in PRC:
1601 Zhangdong Road
Zhangjiang Hi-Tech Park
Shanghai 201203
The People's Republic of China

Principal Place of Business in Hong Kong:
Room 1922, 19/F, Lee Garden One
33 Hysan Avenue
Causeway Bay
Hong Kong

8 June 2026

To the Shareholders

Dear Sir/Madam,

PROPOSED RE-ELECTION OF RETIRING DIRECTORS, PROPOSED ELECTION OF AN INDEPENDENT NON-EXECUTIVE DIRECTOR, PROPOSED RE-APPOINTMENT OF AUDITOR, PROPOSED GRANTING OF GENERAL MANDATES TO BUY BACK SHARES AND TO ISSUE SHARES, AND NOTICE OF ANNUAL GENERAL MEETING

1. INTRODUCTION

The purpose of this circular is to provide the Shareholders with information reasonably necessary to enable you to make a decision on whether to vote for or against the resolutions to be proposed at the Annual General Meeting for the approval of, among other matters, (i)

* *for identification purpose only*

the re-election of retiring Directors; (ii) the election of an independent non-executive Director; (iii) the re-appointment of auditor and (iv) the granting of a Share Buy-back Mandate and Issuance Mandate.

2. PROPOSED RE-ELECTION OF RETIRING DIRECTORS

In accordance with Article 16.19 of the Articles of Association, Mr. Jonathan H. Chou ("Mr. Chou"), Dr. Guoen Liu ("Dr. Liu") and Ms. Weiqin Sun shall retire from offices as Directors at the Annual General Meeting. In addition, in accordance with Article 16.2 of the Articles of Association, Dr. Feng Gu and Dr. Qingbing Men, who were appointed as Directors by the Board on 30 September 2025, shall hold office until the Annual General Meeting. All of the above retiring Directors, being eligible, will offer themselves for re-election at the Annual General Meeting.

Mr. Chou and Dr. Liu have served as independent non-executive Directors for more than 9 years. Mr. Chou and Dr. Liu bring their valuable industry experiences and contribute to the Board's efforts in promoting the best interests of the Company and its Shareholders. Alongside the other independent non-executive Directors, they contribute to ensuring that the interests of all Shareholders are taken into account and that relevant issues are subject to objective and fair consideration by the Board. Mr. Chou and Dr. Liu demonstrate strong independence in discharging their duties and responsibilities with the utmost commitment in upholding the interests of the Shareholders. They expressed individual viewpoints, debated issues and objectively scrutinized management.

Mr. Chou and Dr. Liu have confirmed their independence with reference to the factors set out in Rule 3.13 of the Listing Rules. The nomination committee of the Company (the "Nomination Committee") has reviewed the independence of all independent non-executive Directors, there is no evidence that the services of Mr. Chou and Dr. Liu of over nine years as independent non-executive Directors would have any impact on their independence. Accordingly, the Nomination Committee has recommended to the Board, and the Board has concurred with such recommendation, to include Mr. Chou and Dr. Liu in the list of Directors being eligible for re-election at the Annual General Meeting. The Board considers that the retiring independent non-executive Directors are independent in accordance with the independence guidelines set out in the Listing Rules and will continue to bring valuable business experience, knowledge and professionalism to the Board for its efficient and effective functioning and diversity.

The Nomination Committee has reviewed the structure and composition of the Board, the confirmations and disclosures given by the Directors, the qualifications, skills and experience, time commitment and contribution with reference to the nomination principles and criteria set out in the Company's Board diversity policy and Director nomination policy and the Company's corporate strategy.

The Board, having considered the recommendation of the Nomination Committee, considers that the re-election of the above Directors is in the best interests of the Company and its Shareholders as a whole.

Details of the Directors to be re-elected at the Annual General Meeting are set out in Appendix I to this circular.

3. PROPOSED ELECTION OF AN INDEPENDENT NON-EXECUTIVE DIRECTOR

The Board recommends the election of Dr. Yingyao Chen ("Dr. Chen") as an independent non-executive Director of the Company and a member of Strategic Committee with effect from the conclusion of the Annual General Meeting.

In assessing the proposed appointment, the Board has received from Dr. Chen a written confirmation of his independence pursuant to Rule 3.13 of the Listing Rules. In the confirmation, Dr. Chen has confirmed: (a) his independence as regards each of the factors referred to in Rules 3.13(1) to (8) of the Listing Rules; (b) that he does not have any past or present financial or other interest in the business of the Company or its subsidiaries, or any connection with any core connected person of the Company; and (c) that there are no other factors that may affect his independence. The Nomination Committee has reviewed Dr. Chen's qualifications, experience, and independence. Taking into account the Nomination Committee's recommendation and the confirmation received, the Board considers Dr. Chen to be independent and believes he has the requisite character, integrity, and experience to fulfill the role of an independent non-executive Director.

The biographical details of Dr. Chen are set out in Appendix I to this circular. Save as disclosed in this circular, there are no other matters in relation to the proposed election of Dr. Chen as an independent non-executive Director that need to be brought to the attention of the Shareholders, and there is no information required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules.

4. PROPOSED RE-APPOINTMENT OF AUDITOR

An ordinary resolution will be proposed at the Annual General Meeting to approve the re-appointment of KPMG as the auditor of the Company and to authorise the Board to fix its remuneration.

The estimated audit fee for the audit of the consolidated financial statements of the Group for the financial year ending 31 December 2026 is expected to be in the range of approximately US$3.5 million to US$4.0 million. The estimated audit fee represents a fair and reasonable estimation, after due consideration and arm's length negotiation between the Company and KPMG. The estimation takes into account various factors such as the size and structure of the Group, the nature and complexity of the Group's business, the expected scope, timetable and direction of the audit work and the time and resources deployed by the auditor.

Furthermore, the estimated audit fee assumes there will be no material changes in the Group's businesses and operations, accounting policies or regulatory environment, foreign exchange rates and that the Company will provide timely and adequate assistance and information as required for the audit.

5. PROPOSED GRANTING OF THE SHARE BUY-BACK MANDATE

At the annual general meeting of the Company held on 30 May 2025, a general mandate was granted to the Directors to buy back Shares. Such mandate will lapse at the conclusion of the Annual General Meeting. In order to give the Company the flexibility to buy back Shares if and when appropriate, an ordinary resolution will be proposed at the Annual General Meeting to approve the granting of the Share Buy-back Mandate to the Directors to buy back Shares on the Stock Exchange of not exceeding 10% of the total number of issued Shares (excluding treasury shares) as at the date of passing of the proposed ordinary resolution contained in item 6 of the notice of the Annual General Meeting as set out on pages 19 to 23 of this circular (i.e. a total of 191,737,965 Shares on the basis that the issued share capital of the Company remains unchanged and the Company does not have any treasury shares on the date of the Annual General Meeting). The Directors wish to state that they have no immediate plan to buy back any Shares pursuant to the Share Buy-back Mandate.

An explanatory statement required by the Listing Rules to provide the Shareholders with requisite information reasonably necessary for them to make an informed decision on whether to vote for or against the granting of the Share Buy-back Mandate is set out in Appendix II to this circular.

6. PROPOSED GRANTING OF THE ISSUANCE MANDATE

At the annual general meeting of the Company held on 30 May 2025, a general mandate was granted to the Directors to issue Shares. Such mandate will lapse at the conclusion of the Annual General Meeting. In order to give the Company the flexibility to issue Shares if and when appropriate, an ordinary resolution will be proposed at the Annual General Meeting to approve the granting of the Issuance Mandate to the Directors to allot, issue or deal with additional Shares of not exceeding 20% of the total number of issued Shares (excluding treasury shares) as at the date of passing of the proposed ordinary resolution contained in item 7 of the notice of the Annual General Meeting as set out on pages 19 to 23 of this circular (i.e. a total of 383,475,931 Shares on the basis that the issued share capital of the Company remains unchanged and the Company does not have any treasury shares on the date of the Annual General Meeting). An ordinary resolution to extend the Issuance Mandate by adding the number of Shares bought back by the Company pursuant to the Share Buy-back Mandate will also be proposed at the Annual General Meeting.

7. RESPONSIBILITY STATEMENT

This circular, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all

reasonable enquiries, confirm that to the best of their knowledge and belief, the information contained in this circular is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this document misleading.

8. ANNUAL GENERAL MEETING AND PROXY ARRANGEMENT

The notice of the Annual General Meeting is set out on pages 19 to 23 of this circular.

Pursuant to the Listing Rules and the Articles of Association, any vote of Shareholders at a general meeting must be taken by poll except where the chairman decides to allow a resolution relating to a procedural or administrative matter to be voted on by a show of hands. Article 13.7 of the Articles of Association provides that, at any general meeting a resolution put to the vote of the meeting shall be decided on a poll. According to Article 14.1 of the Articles of Association, every Shareholder present in person or by proxy shall have one vote for each Share registered in his name in the register. An explanation of the detailed procedures of voting by poll will be provided to the Shareholders at the Annual General Meeting. The Company will publish an announcement of the poll results on the websites of the Stock Exchange and the Company after the Annual General Meeting in accordance with Rule 13.39(5) of the Listing Rules.

A form of proxy for use at the Annual General Meeting is enclosed with this circular and such form of proxy is also published on the websites of Hong Kong Exchanges and Clearing Limited (www.hkexnews.hk) and the Company (www.microport.com). To be valid, the form of proxy must be completed and signed in accordance with the instructions printed thereon and deposited, together with the power of attorney or other authority (if any) under which it is signed or a certified copy of that power of attorney or authority at the Company's branch share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong as soon as possible but in any event not later than 10:00 a.m. on 28 June 2026 (Sunday) (Hong Kong time). Completion and delivery of the form of proxy will not preclude you from attending and voting at the Annual General Meeting if you so wish and in such event, your proxy form shall be deemed to be revoked.

For determining the entitlement to attend and vote at the Annual General Meeting, the register of members of the Company will be closed from 25 June 2026 (Thursday) to 30 June 2026 (Tuesday), both days inclusive, during which period no transfer of shares will be registered. The record date for determining the entitlement to attend and vote at Annual General Meeting is 30 June 2026 (Tuesday). In order to be eligible to attend and vote at the Annual General Meeting, all transfer documents of shares, accompanied by the relevant share certificates, must be lodged with the Company's branch share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong, for registration not later than 4:30 p.m. on 24 June 2026 (Wednesday) (Hong Kong Time), being the share last registration date.

9. RECOMMENDATION

The Directors consider that the resolutions in relation to, among others, (i) the proposed re-election of retiring Directors; (ii) the proposed election of an independent non-executive Director; (iii) the proposed re-appointment of auditor; and (iv) the granting of the Share Buy-back Mandate and the Issuance Mandate are in the best interests of the Company and the Shareholders. Accordingly, the Directors recommend the Shareholders to vote in favour of the relevant resolutions to be proposed at the Annual General Meeting.

Yours faithfully,
For and on behalf of the Board
Dr. Zhaohua Chang
Chairman

The following are the details of the Directors proposed to be re-elected or elected at the Annual General Meeting.

(1) Dr. Feng Gu（谷峰）

Dr. Feng Gu ("Dr. Gu"), born in 1972, was appointed as a non-executive Director and a member of each of the nomination committee and the remuneration committee of the Company on 30 September 2025. Dr. Gu has over 20 years of experience in financial management, enterprise management, industrial capital operations, equity investment, and corporate governance. Dr. Gu currently serves as chief finance and investment officer of Shanghai Industrial Investment (Holdings) Company Limited, deputy CEO of Shanghai Industrial Holdings Limited (a company listed on the Stock Exchange (stock code: 0363)), executive director and president of SIIC Shanghai Capital Management Co., Ltd., the chairman of the board of directors of SIIC Shanghai Biomedical Management Consulting Co., Ltd., the chairman of the board of directors of SIIC Shanghai Technology Venture Capital Co., Ltd. and the vice president of Shanghai Services Federation. Dr. Gu has been in charge of finance, investment and financial business in several conglomerates and has extensive experience in mergers and acquisitions, equity investment, reorganization and integration, as well as listing and financing. From 1997 to 2001, Dr. Gu served as head of the financial and accounting department at SAIC General Motors Corporation Limited. From 2001 to 2005, he held positions of deputy manager of the finance department and deputy manager of the asset operation department at Shanghai Automotive Industry Corporation (Group). From 2005 to 2016, he successively served as executive director of capital operations, executive director of finance, and chief financial officer at SAIC Motor Corporation Limited, and concurrently served as the person-in-charge of several subsidiaries. From 2017 to 2020, he co-founded Aiways Automobiles and served as its chief executive officer. From 2020 to 2023, he served as the chief financial and investment officer of Bailian Group Co., Ltd. Dr. Gu holds the title of senior accountant in PRC and is a non-practicing member of China Certified Public Accountants (CPA), a member of The Association of Chartered Certified Accountants ("ACCA") and a member of ACCA China Expert Forum. Dr. Gu currently also serves as a director of Chengdu Kanghua Biological Products Co., Ltd. (a company listed on the Shenzhen Stock Exchange (stock code: 300841), and an independent director of Shanghai Highly (Group) Co., Ltd. (a company listed on the Shanghai Stock Exchange (stock code: 600619)) and from May 2020 to April 2024, he has served as an independent director of Gemdale Corporation (a company listed on the Shanghai Stock Exchange (stock code: 600383)). He obtained his Ph.D in Business Administration from Tongji University in August 2011.

Save as disclosed above, Dr. Gu has not held any directorship in other listed public companies in Hong Kong or overseas in the last three years, and he is not related to any Directors, senior management, other substantial or controlling shareholders (as defined in the Listing Rules) of the Company, nor does he hold any other positions with the Company or any of its subsidiaries.

As at the Latest Practicable Date, Dr. Gu did not have or was not deemed to have any other interests or short positions in the shares or underlying shares of the Company or its associated corporations pursuant to Part XV of the SFO.

Dr. Gu has entered into a letter of appointment with the Company for a term of three years, subject to rotation and re-election at annual general meetings in accordance with the Articles of Association of the Company. Dr. Gu's emolument, if any, will be reviewed by the Board from time to time under the authority granted to the Board by the Shareholders and in accordance with the recommendation of the Remuneration Committee of the Board by reference to his experience and responsibilities, the Company's performance, remuneration policy and prevailing market conditions.

There is no information which is discloseable nor is Dr. Gu involved in any of the matters required to be disclosed pursuant to any of the requirements under Rules 13.51(2)(h) to (v) of the Listing Rules and there are no other matters concerning the appointment of Dr. Gu that need to be brought to the attention of the shareholders of the Company.

(2) Dr. Qingbing Men（門慶兵）

Dr. Qingbing Men ("Dr. Men"), born in 1977, was appointed as a non-executive Director, a member of the audit committee of the Company and the chairman of the strategic committee of the Company on 30 September 2025. Dr. Men has over 20 years of experience in finance and investment. He currently serves as the general manager and deputy party secretary of Shanghai Pudong Innovation Investment and Development (Group) Co., Ltd., and a council member of the Shanghai Institute of Science and Technology Innovation and Finance. From September 2004 to April 2006, Dr. Men worked at Greenland Group based in Shanghai. From April to July 2006, Dr. Men worked at SIIC. From July 2006 to January 2010, he served at the Development and Reform Committee of Pudong New District. From January 2010 to January 2023, Dr. Men worked at the Finance Bureau of Pudong New District, successively holding positions including senior staff member, deputy director, director and deputy director general of the institutional development service division. From January 2023 to March 2024, Dr. Men joined Shanghai Pudong Investment Holdings (Group) Co., Ltd. (now renamed as Shanghai Pudong Innovation Investment and Development (Group) Co., Ltd.), where he served as the deputy general manager and party committee member. Dr. Men obtained his Ph.D. in Technical Economics and Management from Tongji University in September 2004.

Save as disclosed above, Dr. Men has not held any directorship in other listed public companies in Hong Kong or overseas in the last three years, and he is not related to any Directors, senior management, other substantial or controlling shareholders (as defined in the Listing Rules) of the Company, nor does he hold any other positions with the Company or any of its subsidiaries.

As at the Latest Practicable Date, Dr. Men did not have or was not deemed to have any other interests or short positions in the shares or underlying shares of the Company or its associated corporations pursuant to Part XV of the SFO.

Dr. Men has entered into a letter of appointment with the Company for a term of three years, subject to rotation and re-election at annual general meetings in accordance with the Articles of Association of the Company. Dr. Men's emolument, if any, will be reviewed by the Board from time to time under the authority granted to the Board by the Shareholders

and in accordance with the recommendation of the Remuneration Committee of the Board by reference to his experience and responsibilities, the Company's performance, remuneration policy and prevailing market conditions.

There is no information which is discloseable nor is Dr. Men involved in any of the matters required to be disclosed pursuant to any of the requirements under Rules 13.51(2)(h) to (v) of the Listing Rules and there are no other matters concerning the appointment of Dr. Men that need to be brought to the attention of the shareholders of the Company.

(3) Ms. Weiqin Sun（孫維琴）

Ms. Weiqin Sun ("Ms. Sun"), born in 1980, was appointed as a non-executive Director on 30 August 2023. Ms. Sun is currently the general manager of Shanghai Zhangjiang Technology Venture Capital Co., Ltd.. Ms. Sun joined Shanghai Zhangjiang Group in July 2002. She has successively served as the assistant to director of the incubator center of Shanghai Zhangjiang (Group) Co., Ltd., the executive deputy general manager (in charge of overall management), general manager of Shanghai Zhangjiang Business Incubator Management Co., Ltd., the dean of Shanghai Zhangjiang Innovation Institute, and the deputy director of the investment service center of Shanghai Zhangjiang (Group) Co., Ltd., assistant general manager, deputy general manager of Shanghai Zhangjiang Technology Venture Capital Co., Ltd.. Ms. Sun received her master's degree in Business Administration from Fudan University in January 2010.

Save as disclosed above, Ms. Sun did not hold any directorship in other listed public companies in Hong Kong or overseas in the last three years, and she is not related to any Directors, senior management, other substantial or controlling Shareholders (as defined in the Listing Rules) of the Company, nor does she hold any other positions with the Company or any of its subsidiaries.

As at the Latest Practicable Date, Ms. Sun did not have or was not deemed to have any interests or short positions in the shares or underlying shares of the Company or its associated corporations pursuant to Part XV of the SFO.

Ms. Sun has entered into a letter of appointment with the Company for a term of three years, subject to rotation and re-election at annual general meetings in accordance with the Articles of Association of the Company. Ms. Sun's emolument, if any, will be reviewed by the Board from time to time under the authority granted to the Board by the Shareholders and in accordance with the recommendation of the Remuneration Committee of the Board by reference to her experience and responsibilities, the Company's performance, remuneration policy and prevailing market conditions.

There is no information which is discloseable nor is Ms. Sun involved in any of the matters required to be disclosed pursuant to any of the requirements under Rule 13.51(2)(h) to (v) of the Listing Rules and there are no other matters concerning Ms. Sun that need to be brought to the attention of the Shareholders.

(4) Mr. Jonathan H. Chou（周嘉鴻）

Mr. Jonathan H. Chou ("Mr. Chou"), born in 1964, was appointed as our Independent Non-executive Director on 3 September 2010. Mr. Chou is a seasoned finance executive and advisor with over 30 years of international experience across the semiconductor, electronics and industrial sectors. Mr. Chou was most recently the Chief Financial Officer of UTAC Holdings Ltd., a global semiconductor assembly and test services provider, where he also oversaw the group's information technology and human resources functions. Prior to that, he served as Chief Financial Officer of Kulicke & Soffa Industries. (Nasdaq: KLIC) ("K&S"), a leading provider of semiconductor packaging and electronic assembly solutions, and concurrently held the position of interim Chief Executive Officer of K&S from 2015 to 2016. During his tenure at K&S, he was also responsible for the company's global IT and facilities operations. Earlier in his career, he held senior finance leadership roles with multinational corporations across industrial and technology sectors. Mr. Chou currently serves as an independent non-executive director of MicroPort CardioFlow Medtech Corporation（微创心通医疗科技有限公司, a subsidiary of the Company, listed on the Hong Kong Stock Exchange (stock code: 2160)) and Shanghai MicroPort MedBot (Group) Co., Ltd.（上海微创医疗机器人(集团)股份有限公司, a subsidiary of the Company, listed on the Hong Kong Stock Exchange (stock code: 2252)). Mr. Chou also currently serves as the chairman of the board of directors of the Emerging Markets Investors Alliance (a non-profit organization dedicated to advancing sustainable governance among institutional investors) and provides advisory services to several private equity-backed companies, including AddVita Pte. Ltd., an Asian healthcare distribution platform invested in by SeaTown, a fund under Temasek. Mr. Chou holds an MBA from Duke University's Fuqua School of Business. He has served since 2013 on the East Asia Regional Advisory Board of Duke University's Fuqua School of Business.

Save as disclosed above, Mr. Chou did not hold any directorship in other listed public companies in Hong Kong or overseas in the last three years, and he is not related to any Directors, senior management, other substantial or controlling Shareholders (as defined in the Listing Rules) of the Company, nor does he hold any other positions with the Company or any of its subsidiaries.

As at the Latest Practicable Date, Mr. Chou had the following interests in shares or underlying shares of the Company and its associated corporations pursuant to Part XV of the SFO:

Name of the Company/ associated corporations	Number of Shares	Approximate percentage of the issued share capital of the Company/ associated corporations
The Company	167,590 *(Note 1)*	0.01%
MicroPort Cardioflow MedTech Corporation	449,683 *(Note 2)*	0.00%

Notes:

1. Mr. Chou was interested in (i) 161,290 underlying Shares of the Company by virtue of the options granted to him under the shares scheme of the Company and (ii) 6,300 Shares of the Company.

2. Mr. Chou was interested in the underlying shares of MicroPort Cardioflow MedTech Corporation by virtue of the options granted to him under the shares scheme of the MicroPort Cardioflow MedTech Corporation.

Save as disclosed above, Mr. Chou did not have or was not deemed to have any other interests or short positions in the shares or underlying shares of the Company or its associated corporations pursuant to Part XV of the SFO.

Mr. Chou has entered into a letter of appointment with the Company for a term of three years. Mr. Chou is subject to retirement by rotation and re-election at annual general meetings in accordance with the Articles of Association of the Company. Mr. Chou's emolument will be reviewed by the Board from time to time under the authority granted to the Board by the Shareholders and in accordance with the recommendation of the remuneration committee of the Board by reference to his experience and responsibilities, the Company's performance, remuneration policy and prevailing market conditions.

There is no information which is discloseable nor is Mr. Chou involved in any of the matters required to be disclosed pursuant to any of the requirements under Rule 13.51(2)(h) to (v) of the Listing Rules and there are no other matters concerning Mr. Chou that need to be brought to the attention of the Shareholders.

(5) Dr. Guoen Liu（劉國恩）

Dr. Guoen Liu ("Dr. Liu"), born in 1957, was appointed as our Independent Non-executive Director on 3 September 2010. Dr. Liu is a noted scholar in the fields of health and development economics, health reform and pharmaceutical economics. Dr. Liu currently serves as Dean of Peking University Institute for Global Health and Development, MOE Yangtze River Scholar distinguished professor of economics at the Peking University National School of Development and a member of the Chinese Academy of Medical Sciences. From 2000 to 2006, Dr. Liu was tenured associate professor of University of North Carolina at Chapel Hill. From 1994 to 2000, Dr. Liu was assistant professor of University of Southern California. Dr. Liu also serves as editor or associate editor in various journals in the field of health economics and pharmaceutical economics. Dr. Liu currently serves as an independent non-executive director of Shanghai MicroPort MedBot (Group) Co., Ltd.（上海微創醫療機器人(集團)股份有限公司, a subsidiary of the Company, listed on the Hong Kong Stock Exchange (stock code: 2252)) and an independent director of Yunnan Baiyao Group Co., Ltd.（雲南白藥集團股份有限公司, a company listed on the Shenzhen Stock Exchange (stock code: 00538)). From February 2021 to July 2024, Dr. Liu was an independent director of SciClone Pharmaceuticals (Holdings) Limited（賽生藥業控股有限公司, a company listed on Hong Kong Stock Exchange (stock code: 06600) and the listing of its shares was withdrawn with effect from 5 July 2024). Dr. Liu received his Ph.D. in economics from the City University of New York Graduate Center in 1991, and finished his postdoctoral learning in health economics at Harvard University in 1994.

Save as disclosed above, Dr. Liu did not hold any directorship in other listed public companies in Hong Kong or overseas in the last three years, and he is not related to any Directors, senior management, other substantial or controlling Shareholders (as defined in the Listing Rules) of the Company, nor does he hold any other positions with the Company or any of its subsidiaries.

As at the Latest Practicable Date, Dr. Liu was interested in 161,290 underlying Shares of the Company by virtue of the options granted to him under the share option schemes of the Company, representing approximately 0.01% of the issued share capital of the Company. Save as disclosed above, Dr. Liu did not have or was not deemed to have any other interests or short positions in the shares or underlying shares of the Company or its associated corporations pursuant to Part XV of the SFO.

Dr. Liu has entered into a letter of appointment with the Company for a term of three years. Dr. Liu is subject to retirement by rotation and re-election at annual general meetings in accordance with the Articles of Association of the Company. Dr. Liu's emolument will be reviewed by the Board from time to time under the authority granted to the Board by the Shareholders and in accordance with the recommendation of the remuneration committee of the Board by reference to his experience and responsibilities, the Company's performance, remuneration policy and prevailing market conditions.

There is no information which is discloseable nor is Dr. Liu involved in any of the matters required to be disclosed pursuant to any of the requirements under Rule 13.51(2)(h) to (v) of the Listing Rules and there are no other matters concerning Dr. Liu that need to be brought to the attention of the Shareholders.

(6) Dr. Yingyao Chen（陳英耀）

Dr. Yingyao Chen ("Dr. Chen"), born in 1968, is an expert in health technology assessment and hospital management. Dr. Chen currently serves as a Professor and Vice Dean of the School of Public Health, Fudan University, Director of the Key Laboratory of Health Technology Assessment of the National Health Commission, Director of the World Health Organization Collaborating Centre for Health Technology Assessment, Chairman of the Health Technology Assessment Professional Committee of the China Medicinal Biotech Association, Chairman of the Health Technology Assessment and Policy Research Professional Committee of the China Association for Medical Devices Industry, Vice Chairman of the Health Technology and Economic Evaluation Professional Committee of the China Health Economics Association, and Vice President of Shanghai Association for Maternal and Child Health and Improving Birth Outcome and Child Development.

Dr. Chen has long been engaged in research in health technology assessment, hospital management and public health programme evaluation. He has led a number of research projects of the World Health Organization, the World Bank, the National Health Commission, the National Healthcare Security Administration, among others. Dr. Chen has served as chief editor of a number of national core textbooks, and has published extensively as first author or corresponding author in domestic and international core journals, including the British Medical Journal. From 1991 to 1999, Dr. Chen served as an Assistant Professor

and Lecturer at the School of Public Health of Shanghai Medical University. From 1999 to 2001, he was a visiting scholar at the UCLA Fielding School of Public Health. Dr. Chen returned to the School of Public Health of Fudan University in 2001.

Dr. Chen obtained his Bachelor's degree in Medicine and Master's degree in Medicine from Shanghai Medical University in 1991 and 1997, respectively, and obtained his Doctoral degree in Management from Fudan University in 2006.

Save as disclosed above, Dr. Chen did not hold any directorship in other listed public companies in Hong Kong or overseas in the last three years, and he is not related to any Directors, senior management, other substantial or controlling Shareholders (as defined in the Listing Rules) of the Company, nor does he hold any other positions with the Company or any of its subsidiaries.

As at the Latest Practicable Date, Dr. Chen was not interested or deemed to be interested in any shares, underlying shares or debentures of the Company or any of its associated corporations within the meaning of Part XV of the SFO.

Dr. Chen will enter into a letter of appointment with the Company under which he will be appointed for a term of three years, subject to rotation and re-election at annual general meetings in accordance with the Articles of Association of the Company. Dr. Chen's emolument, will be determined by the Board from time to time under the authority granted to the Board by the shareholders and in accordance with the recommendation of the remuneration committee of the Board by reference to his experience and responsibilities, the Company's performance, remuneration policy and prevailing market conditions.

There is no information which is disclosable nor is Dr. Chen involved in any of the matters required to be disclosed pursuant to any of the requirements under Rules 13.51(2)(h) to (v) of the Listing Rules and there are no other matters concerning Dr. Chen that need to be brought to the attention of the Shareholders.

1. SHARE CAPITAL

As at the Latest Practicable Date, the issued share capital of the Company comprised 1,917,379,655 Shares and the Company did not have any treasury shares.

Subject to the passing of the ordinary resolution set out in item 6 of the notice of the Annual General Meeting in respect of the granting of the Share Buy-back Mandate and on the basis that the issued share capital of the Company remains unchanged on the date of the Annual General Meeting, i.e. being 1,917,379,655 Shares, the Directors would be authorized under the Share Buy-back Mandate to buy back, during the period in which the Share Buy-back Mandate remains in force, a total of 191,737,965 Shares, representing 10% of the total number of Shares in issue (excluding treasury shares) as at the date of the Annual General Meeting.

2. REASONS FOR SHARE BUY-BACK

The Directors believe that the granting of the Share Buy-back Mandate is in the best interests of the Company and the Shareholders as a whole.

When exercising the Share Buy-back Mandate, the Directors may, subject to market conditions and the Company's capital management needs at the relevant time of the buy-backs, resolve to cancel the Shares bought back following settlement of any such buy-back or hold them as treasury shares. Shares bought back for cancellation may, depending on the market conditions and funding arrangements at the time, lead to an enhancement of the net asset value per Share and/or earnings per Share. On the other hand, Shares bought back and held by the Company as treasury shares may be resold on the market at market prices to raise funds for the Company, or transferred or used for other purposes, and subject to compliance with the Listing Rules, the Memorandum of Association, the Articles of Association, and the laws of the Cayman Islands, Share buy-backs will only be made when the Directors believe that such a buy-back will benefit the Company and the Shareholders.

3. FUNDING OF SHARE BUY-BACK

Share buy-backs pursuant to the Share Buy-back Mandate would be financed entirely from the Company's available cash flow or working capital facilities. The Company may only apply funds legally available for Shares buy-back in accordance with its Memorandum of Association and Articles of Association, the laws of the Cayman Islands and/or any other applicable laws, as the case may be.

4. IMPACT OF SHARE BUY-BACK

There might be a material adverse impact on the working capital or gearing position of the Company (as compared with the position disclosed in the audited accounts contained in the annual report of the Company for the year ended 31 December 2025) in the event that the Share Buy-back Mandate was to be carried out in full at any time during the proposed buy-back period. However, the Directors do not intend to exercise the Share Buy-back

Mandate to such extent as would, in the circumstances, have a material adverse effect on the working capital requirements of the Company or the gearing levels which in the opinion of the Directors are from time to time appropriate for the Company.

5. MARKET PRICES OF SHARES

The highest and lowest prices per Share at which Shares have traded on the Stock Exchange during each of the previous 12 months up to and including the Latest Practicable Date were as follows:

Month	Highest *HK$*	Lowest *HK$*
2025		
May	7.63	6.48
June	9.15	6.94
July	15.56	8.04
August	15.12	11.35
September	15.25	12.50
October	16.28	11.50
November	12.13	10.06
December	11.90	9.80
2026		
January	14.16	10.55
February	11.65	10.56
March	10.91	8.99
April	9.73	8.57
May	8.90	7.38
June *(up to the Latest Practicable Date)*	7.77	7.48

6. GENERAL

To the best of their knowledge and having made all reasonable enquiries, none of the Directors nor any of their respective close associates (as defined in the Listing Rules) have any present intention to sell any Shares to the Company in the event that the granting of the Share Buy-back Mandate is approved by the Shareholders.

The Company has not been notified by any core connected persons of the Company that they have a present intention to sell any Shares to the Company, or that they have undertaken not to sell any Shares held by them to the Company in the event that the granting of the Share Buy-back Mandate is approved by the Shareholders.

The Directors will exercise the power of the Company to buy back Shares pursuant to the Share Buy-back Mandate in accordance with the Listing Rules and the applicable laws of the Cayman Islands. Neither this explanatory statement nor the proposed share buy-back has any unusual features.

7. TAKEOVERS CODE

If as a result of a buy-back of Shares pursuant to the Share Buy-back Mandate, a Shareholder's proportionate interest in the voting rights of the Company increases, such increase will be treated as an acquisition of voting rights for the purposes of the Takeovers Code. Accordingly, a Shareholder or a group of Shareholders acting in concert (within the meaning under the Takeovers Code), depending on the level of increase in the Shareholder's interest, could obtain or consolidate control of the Company and thereby become obliged to make a mandatory offer in accordance with Rule 26 of the Takeovers Code.

As at the Latest Practicable Date, the Company did not have a controlling Shareholder within the meaning of the Listing Rules. To the best of the knowledge and belief of the Directors, Maxwell Maxcare Science Foundation Limited (together with its controlled corporation) is the largest substantial Shareholder holding 448,230,446 Shares, representing approximately 23.38% of the total number of Shares in issue. In the event that the Directors exercise the power to repurchase Shares in full pursuant to the Share Buy-back Mandate, (if the present shareholdings remain the same and the Company does not have any treasury shares) the shareholding of Maxwell Maxcare Science Foundation Limited in the Company will be increased to approximately 25.97% of the issued share capital of the Company and such increase would not give rise to an obligation to make a mandatory general offer under Rule 26 of the Takeovers Code.

To the best knowledge of the Company, the Directors are not aware of any consequences which would arise under the Takeovers Code as a result of an exercise of the proposed Share Buy-back Mandate. Moreover, the Directors will not repurchase Shares on the Stock Exchange if such repurchase would violate the requirements under Rule 8.08 of the Listing Rules.

8. SHARE BUY-BACK MADE BY THE COMPANY

During the 6 months prior to the Latest Practicable Date, the Company had not bought back any of the Shares (whether on the Stock Exchange or otherwise).

9. TREASURY SHARES

For any treasury shares of the Company deposited with CCASS pending resale on the Stock Exchange, the Company shall, upon approval by the Board, implement appropriate interim measures, which include (without limitation), (i) procuring its broker not to give any instructions to Hong Kong Securities Clearing Company Limited to vote at general meetings for the treasury shares deposited with CCASS; (ii) in the case of dividends or distributions (if any and where applicable), withdrawing the treasury shares from CCASS, and either re-register them in its own name as treasury shares or cancel them, in each case before the relevant record date for the dividends or distributions; and (iii) taking any other measures to ensure that it will not exercise any Shareholders' rights or receive any entitlements which would otherwise be suspended under the applicable laws if those Shares were registered in its own name as treasury shares.

MicroPort®

MicroPort Scientific Corporation

微創醫療科學有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 00853)

NOTICE IS HEREBY GIVEN that the Annual General Meeting of MicroPort Scientific Corporation (the "**Company**") will be held at 1601 Zhangdong Road, Zhangjiang Hi-Tech Park, Shanghai 201203, the People's Republic of China on 30 June 2026 (Tuesday) at 10:00 a.m. for the following purposes:

To consider and, if thought fit, pass with or without amendments, the following resolutions as ordinary resolutions:

ORDINARY RESOLUTIONS

1. To receive the audited consolidated financial statements of the Company and the reports of the directors and auditor for the year ended 31 December 2025.

2. To re-elect the following directors of the Company (the "**Directors**") pursuant to the Articles of Association (the "**Articles of Association**") of the Company:

   (i) To re-elect Dr. Feng Gu as a non-executive Director of the Company;

   (ii) To re-elect Dr. Qingbing Men as a non-executive Director of the Company;

   (iii) To re-elect Ms. Weiqin Sun as a non-executive Director of the Company;

   (iv) To re-elect Mr. Jonathan H. Chou as an independent non-executive Director of the Company; and

   (v) To re-elect Dr. Guoen Liu as an independent non-executive Director of the Company.

3. To elect Dr. Yingyao Chen as an independent non-executive Director of the Company.

4. To authorize the board of directors of the Company (the "**Board**") to fix the respective Directors' remuneration.

5. To re-appoint KPMG as auditor and to authorize the Board to fix its remuneration.

* *for identification purpose only*

6. "**THAT**:

(a) subject to paragraph (b) below, a general mandate be and is hereby generally and unconditionally given to the directors of the Company to exercise during the Relevant Period (as defined below) all the powers of the Company to buy back its shares in accordance with all applicable laws, rules and regulations;

(b) the total number of shares of the Company to be bought back pursuant to the mandate in paragraph (a) above shall not exceed 10% of the total number of issued shares of the Company (excluding treasury shares) as at the date of passing of this resolution, and if any subsequent consolidation or subdivision of shares is conducted, the maximum number of shares that may be bought back under the mandate in paragraph (a) above as a percentage of the total number of issued shares (excluding treasury shares) at the date immediately before and after such consolidation or subdivision shall be the same; and

(c) for the purposes of this resolution:

"Relevant Period" means the period from the passing of this resolution until whichever is the earliest of:

(i) the conclusion of the next annual general meeting of the Company;

(ii) the expiration of the period within which the next annual general meeting of the Company is required by the Articles of Association of the Company or any applicable laws to be held; and

(iii) the date on which the authority set out in this resolution is revoked or varied by an ordinary resolution of the shareholders in general meeting."

7. "**THAT**:

(a) subject to paragraph (c) below, a general mandate be and is hereby generally and unconditionally given to the directors of the Company during the Relevant Period (as defined below) to allot, issue and deal with additional shares in the capital of the Company and/or to resell treasury shares of the Company (if permitted under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**")), and to make or grant offers, agreements and options which might require the exercise of such powers;

(b) the mandate in paragraph (a) above shall authorize the directors of the Company to make or grant offers, agreements and options during the Relevant Period which would or might require the exercise of such powers after the end of the Relevant Period;

(c) the aggregate number of shares allotted or agreed conditionally or unconditionally to be allotted by the directors together with the treasury shares of the Company resold pursuant to the mandate in paragraph (a) above, otherwise than pursuant to:

(i) a Rights Issue (as defined below);

(ii) the exercise of options under a share option scheme of the Company; and

(iii) any scrip dividend scheme or similar arrangement providing for the allotment of shares in lieu of the whole or part of a dividend on shares of the Company in accordance with the Articles of Association of the Company,

shall not exceed 20% of the total number of issued shares of the Company (excluding treasury shares) as at the date of passing of this resolution, and if any subsequent consolidation or subdivision of shares is conducted, the maximum number of shares that may be issued together with the treasury shares which may be resold (if permitted under the Listing Rules) under the mandate in paragraph (a) above as a percentage of the total number of issued shares (excluding treasury shares) at the date immediately before and after such consolidation or subdivision shall be the same; and

(d) for the purposes of this resolution:

"Relevant Period" means the period from the passing of this resolution until whichever is the earliest of:

(i) the conclusion of the next annual general meeting of the Company;

(ii) the expiration of the period within which the next annual general meeting of the Company is required by the Articles of Association of the Company or any applicable laws to be held; and

(iii) the date on which the authority set out in this resolution is revoked or varied by an ordinary resolution of the shareholders in general meeting.

"Right Issue" means an offer of shares open for a period fixed by the directors to holders of shares of the Company or any class thereof on the register on a fixed record date in proportion to their then holdings of such shares or class thereof (subject to such exclusions or other arrangements as the directors may deem necessary or expedient in relation to fractional entitlements or having regard to any restrictions or obligations under the laws of any relevant jurisdiction or the requirements of any recognized regulatory body or any stock exchange)."

8. "**THAT** conditional upon the passing of the resolutions set out in items 6 and 7 of the notice convening this meeting (the "**Notice**"), the general mandate referred to in the resolution set out in item 7 of the Notice be and is hereby extended by the addition to the aggregate number of shares which may be allotted and issued or agreed conditionally or unconditionally to be allotted and issued by the directors together with the treasury shares of the Company resold pursuant to such general mandate of the number of shares bought back by the Company pursuant to the mandate referred to in resolution set out in item 6 of the Notice, provided that such amount shall not exceed 10% of the total number of issued shares of the Company (excluding treasury shares) as at the date of passing of this resolution."

By Order of the Board
Dr. Zhaohua Chang
Chairman

Shanghai, the People's Republic of China, 8 June 2026

Notes:

1. All resolutions at the meeting will be taken by poll pursuant to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**"). Article 13.7 of the Articles of Association provides that, at any general meeting a resolution put to the vote of the meeting shall be decided on a poll. According to Article 14.1 of the Articles of Association, every shareholder present in person or by proxy shall have one vote for each share registered in his name in the register. An explanation of the detailed procedures of conducting a poll will be provided to shareholders at the meeting. The results of the poll will be published on the websites of Hong Kong Exchanges and Clearing Limited and the Company in accordance with the Listing Rules.

2. Any shareholder of the Company entitled to attend and vote at the meeting is entitled to appoint a proxy to attend and on a poll, vote instead of him. A proxy need not be a shareholder of the Company.

3. In order to be valid, the form of proxy together with the power of attorney or other authority, if any, under which it is signed or a certified copy of that power of attorney or authority, must be deposited at the Company's branch share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong not later than 10:00 a.m. on 28 June 2026 (Sunday) (Hong Kong time). Delivery of the form of proxy shall not preclude a shareholder of the Company from attending and voting in person at the meeting and, in such event, the instrument appointing a proxy shall be deemed to be revoked.

4. For determining the entitlement to attend and vote at the above meeting, the register of members of the Company will be closed from 25 June 2026 (Thursday) to 30 June 2026 (Tuesday), both dates inclusive, during which period no transfer of shares will be registered. The record date for determining the entitlement to attend and vote at the above meeting is 30 June 2026 (Tuesday). In order to be eligible to attend and vote at the meeting, unregistered holders of shares of the Company shall ensure that all transfer documents of shares accompanied by the relevant share certificates must be lodged with the Company's branch share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong for registration not later than 4:30 p.m. on 24 June 2026 (Wednesday) (Hong Kong time), being the last share registration date.

5. If a Typhoon Signal No. 8 or above is hoisted or a Black Rainstorm Warning Signal is in force at any time between 6:30 a.m. and 9:00 a.m. on the day of the meeting, the meeting will be adjourned. The Company will post an announcement on the Company's website (www.microport.com) and the HKEXnews website (www.hkexnews.hk) to notify Shareholders of the date, time and place of the adjourned meeting.

   The meeting will be held as scheduled when an Amber or a Red Rainstorm Warning Signal is in force. Shareholders should decide on their own whether they would attend the meeting under bad weather conditions bearing in mind their own situations.

6. A circular containing further details concerning items 2, 3 and 5 to 8 set out in this Notice will be sent to all shareholders of the Company.

As at the date of this notice, the executive director of the Company is Dr. Zhaohua Chang; the non-executive directors of the Company are Dr. Feng Gu, Dr. Qingbing Men and Ms. Weiqin Sun; and the independent non-executive directors of the Company are Mr. Jonathan H. Chou, Dr. Guoen Liu and Mr. Chunyang Shao.